Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice.

Autor:	Li C; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA., Goncalves KA; Magenta Therapeutics, Cambridge, MA., Raskó T; AG 'Mobile DNA Lab,' Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany., Pande A; AG 'Mobile DNA Lab,' Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany., Gil S; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA., Liu Z; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA., Izsvák Z; AG 'Mobile DNA Lab,' Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany., Papayannopoulou T; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA., Davis JC; Magenta Therapeutics, Cambridge, MA., Kiem HP; Fred Hutchinson Cancer Research Center, Seattle, WA; and.; Division of Medical Oncology, Department of Medicine, and.; Department of Pathology, University of Washington, Seattle, WA., Lieber A; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA.; Department of Pathology, University of Washington, Seattle, WA.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2021 Mar 09; Vol. 5 (5), pp. 1239-1249.
DOI:	10.1182/bloodadvances.2020003714
Abstrakt:	We have developed an in vivo hemopoietic stem cell (HSC) gene therapy approach without the need for myelosuppressive conditioning and autologous HSC transplantation. It involves HSC mobilization and IV injection of a helper-dependent adenovirus HDAd5/35++ vector system. The current mobilization regimen consists of granulocyte colony-stimulating factor (G-CSF) injections over a 4-day period, followed by the administration of plerixafor/AMD3100. We tested a simpler, 2-hour, G-CSF-free mobilization regimen using truncated GRO-β (MGTA-145; a CXCR2 agonist) and plerixafor in the context of in vivo HSC transduction in mice. The MGTA-145+plerixafor combination resulted in robust mobilization of HSCs. Importantly, compared with G-CSF+plerixafor, MGTA-145+plerixafor led to significantly less leukocytosis and no elevation of serum interleukin-6 levels and was thus likely to be less toxic. With both mobilization regimens, after in vivo selection with O6-benzylguanine (O6BG)/BCNU, stable GFP marking was achieved in >90% of peripheral blood mononuclear cells. Genome-wide analysis showed random, multiclonal vector integration. In vivo HSC transduction after mobilization with MGTA-145+plerixafor in a mouse model for thalassemia resulted in >95% human γ-globin+ erythrocytes at a level of 36% of mouse β-globin. Phenotypic analyses showed a complete correction of thalassemia. The γ-globin marking percentage and level were maintained in secondary recipients, further demonstrating that MGTA145+plerixafor mobilizes long-term repopulating HSCs. Our study indicates that brief exposure to MGTA-145+plerixafor may be advantageous as a mobilization regimen for in vivo HSC gene therapy applications across diseases, including thalassemia and sickle cell disease. (© 2021 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu